Gastroenteritis caused by Campylobacter spp. is usually self-limiting and requires no antimicrobial treatment except in severe cases and immunocompromised patients. The uncontrolled use of antibiotics, especially in the poultry industry, has resulted in a significant increase in fluoroquinolone (FQ) and macrolide resistance in strains isolated from broiler sources, which is considered a public health concern worldwide. In this study, 42 Campylobacter isolates of chicken origin confirmed by PCR as Campylobacter jejuni (n = 28) or Campylobacter coli (n = 14) isolated during the period September 2015 to July 2016 from Zagazig City, Sharqia Governorate, were used. Their susceptibility to eight FQs was determined by the Kirby–Bauer disk diffusion method. Campylobacter jejuni ATCC1 29428 and C. coli ATCC1 33559TM were used as quality control strains. The FQ antibiotics (Oxoid Ltd., Basingstoke, UK) tested included nalidixic acid, ciprofloxacin, norfloxacin, ofloxacin, enrofloxacin, lomeflox- acin, levofloxacin and gatifloxacin. The broth microdilution method was also carried out to determine the antimicrobial minimum inhibitory concentrations (MICs). DNA from the most highly resistant isolates according to the MIC (seven C. jejuni and three C. coli) was extracted and the QRDR of the gyrA gene was amplified and sequenced. The gyrA sequences were assigned in GenBank with accession nos. MG773479–MG773488.